TITLE

Cost-effectiveness of second-line antihyperglycemic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin

AUTHOR(S)
Klarenbach, Scott; Cameron, Chris; Singh, Sumeet; Ur, Ehud
PUB. DATE
November 2011
SOURCE
CMAJ: Canadian Medical Association Journal;11/8/2011, Vol. 183 Issue 16, pE1213
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Metformin is widely accepted as first-line pharmacotherapy for patients with type 2 diabetes mellitus when glycemic control cannot be achieved by lifestyle interventions alone. However, uncertainty exists regarding the optimal second-line therapy for patients whose diabetes is inadequately controlled bymetformin monotherapy. Increased use of newer, more costly agents, along with the rising incidence of type 2 diabetes, carries significant budgetary implications for health care systems. We conducted this analysis to determine the relative costs, benefits and cost-effectiveness of options for second-line treatment of type 2 diabetes. Methods: We used the United Kingdom Prospective Diabetes Study Outcomes Model to forecast diabetes-related complications, quality-adjusted life-years and costs of alternative second-line therapies available in Canada for adults with type 2 diabetes inadequately controlled by metformin. We obtained clinical data from a systematic review and mixed treatment comparison meta-analysis, and we obtained information on costs and utilities from published sources. We performed extensive sensitivity analyses to test the robustness of results to variation in inputs and assumptions. Results: Sulphonylureas, when added to metformin, were associated with the most favourable cost-effectiveness estimate, with an incremental cost of $12 757 per qualityadjusted life-year gained, relative to continued metformin monotherapy. Treatment with other agents, including thiazolidinediones and dipeptidyl peptidase-4 inhibitors, had unfavourable cost-effectiveness estimates compared with sulphonylureas. These results were robust to extensive sensitivity analyses. Interpretation: For most patients with type 2 diabetes that is inadequately controlled with metformin monotherapy, the addition of asulphonylurea represents the most cost-effective second-line therapy.
ACCESSION #
67261103

 

Related Articles

  • Cost Effectiveness of Saxagliptin and Metformin versus Sulfonylurea and Metformin in the Treatment of Type 2 Diabetes Mellitus in Germany. Erhardt, Wilma; Bergenheim, Klas; Duprat-Lomon, Isabelle; McEwan, Phil // Clinical Drug Investigation;2012, Vol. 32 Issue 3, p189 

    Background: The lack of adequate glycaemic control for patients with type 2 diabetes mellitus (T2DM), especially with existing second-line therapies, represents an unmet medical need. Of the newer therapies, the incretin-based medicines, such as saxagliptin, look promising to consolidate...

  • Newer insulins in type 2 diabetes. Gale, Edwin A. M. // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;9/22/2012, Vol. 345 Issue 7874, p44 

    No abstract available.

  • Lifestyle changes pay off for diabetes.  // PharmacoEconomics & Outcomes News;7/25/2009, Issue 583, p4 

    The article discusses studies on the cost effectiveness of lifestyle interventions aimed at preventing type 2 diabetes mellitus (T2DM) in high risk individuals. A diabetes progression model was used to assess the cost effectiveness of the intensive lifestyle and metformin interventions in the...

  • Success for saxagliptin in South Africa.  // PharmacoEconomics & Outcomes News;6/23/2012, Issue 656, p11 

    This section cites 3 studies on the cost-effectiveness of saxagliptin (Onglyza) for patients with type 2 diabetes mellitus, presented at the 17th Annual International Meeting of the International Society of Pharmacoeconomics and Outcomes Research. A. Juarez-Garcia and colleagues looked at the...

  • Cost-effectiveness of insulin glargine versus sitagliptin in insulin naïve patients with type 2 diabetes mellitus. Brown, S. T.; Sauriol, L. // Journal of Population Therapeutics & Clinical Pharmacology;2014, Vol. 21 Issue 1, pe132 

    Background: In the EASIE (Evaluation of insulin glargine versus Sitagliptin in Insulin-naive patients) trial, insulin glargine demonstrated a significant reduction in HbA1c compared to sitagliptin in type 2 diabetics who are inadequately controlled with metformin). The objective of this study...

  • Combination Therapy of Canagliflozin and Metformin Extended Release Improves A1C Levels.  // Journal of Psychosocial Nursing & Mental Health Services;2015, Vol. 53 Issue 8, p9 

    No abstract available.

  • Pioglitazone combination therapy good value in type 2 DM.  // PharmacoEconomics & Outcomes News;4/10/2004, Issue 450, p11 

    Discusses research being done on the cost effectiveness of combination therapy with pioglitazone for type 2 diabetes mellitus. Reference to a study by K. Neeser and colleagues, published in a 2004 issue of "PharmacoEconomics" journal; Benefits of the therapy for overweight diabetics; Use of a...

  • The next step for insulin-resistant diabetics. R.M.D. // Cortlandt Forum;3/25/96, Vol. 9 Issue 3, p65 

    Discusses the advantages of adding oral agents to the regular medication regimen for an insulin-resistant patient with type II diabetes. Likelihood that such patients will not respond to oral agents.

  • Once-daily insulin-sparing sulfonylurea for noninsulin-dependent diabetics.  // Modern Medicine;Feb96, Vol. 64 Issue 2, p37 

    Reports that the United States Food and Drug Administration has cleared glimepiride (Amaryl) an insulin-sparing sulfonylurea for non-insulin dependent diabetics for marketing. Recommended dose; Side effects; Contraindications.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics